Life Science & Biotechnology Archives - Page 2 of 9

12th May 2021

Federal budget 2021: patent box regime announced for Australian medical and biotechnology patents

As part of Federal budget measures to foster innovation, commercialisation, and manufacturing in Australia, the Federal Government has announced yesterday the introduction of a patent box tax regime for...

As part of Federal budget measures to foster innovation, commercialisation, and manufacturing in Australia, the Federal Government has announced...

22nd Mar 2021

TGA proposes far-reaching changes to support the repurposing of prescription medicines

The Therapeutic Goods Administration (TGA) has commenced a timely public consultation into the repurposing of prescription medicines, which seeks to better understand the incentives and potential hurdles influencing sponsors’...

The Therapeutic Goods Administration (TGA) has commenced a timely public consultation into the repurposing of prescription medicines, which seeks...

16th Feb 2021

Long-running patent dispute relating to Lundbeck’s Lexapro reaches High Court for a third time

Sandoz Pty Ltd v H Lundbeck A/S FCAFC 133 (4 August 2020) In the long-running patent dispute relating to Lundbeck’s blockbuster antidepressant, Lexapro® (escitalopram), the Full Court of Australia’s...

Sandoz Pty Ltd v H Lundbeck A/S FCAFC 133 (4 August 2020) In the long-running patent dispute relating to...

5th Feb 2021

Pfizer preliminary discovery attempt on ERELZI fails

In this Federal Court case, Pfizer’s attempt to obtain documentation from Sandoz regarding its ERELZI etanercept product failed, Justice Burley finding that undertakings provided by Sandoz to give notice...

In this Federal Court case, Pfizer’s attempt to obtain documentation from Sandoz regarding its ERELZI etanercept product failed, Justice...

3rd Feb 2021

MSD blocked from raising public interest defence to injunction in Prevnar vaccine case

Merck Sharp & Dohme Corp v Wyeth LLC (No 4) FCA 1719 In a previous article, we discussed Justice Stephen Burley’s finding that a Wyeth patent covering certain vaccines...

Merck Sharp & Dohme Corp v Wyeth LLC (No 4) FCA 1719 In a previous article, we discussed Justice...

1st Dec 2020

Biological deposits under the Budapest Treaty

In order to obtain patent protection in Australia, an invention must be novel, involve an inventive step and have industrial applicability. There is also a disclosure and enablement requirement...

In order to obtain patent protection in Australia, an invention must be novel, involve an inventive step and have...

18th Nov 2020

Pfizer suffers setback in ENBREL battle

Pfizer suffered a setback last week in its Australian battle to protect ENBREL (etanercept), when its preliminary discovery application against Sandoz was dismissed by Justice Burley in the Federal...

Pfizer suffered a setback last week in its Australian battle to protect ENBREL (etanercept), when its preliminary discovery application...

3rd Nov 2020

The bar has been raised: Prevnar® vaccine case demonstrates the impact of Australian patent law reforms

Merck Sharp & Dohme Corporation v Wyeth LLC (No 3) FCA 1477 Summary Australia’s Federal Court has delivered judgment in a dispute concerning patents covering improvements in vaccines against Streptococcus...

Merck Sharp & Dohme Corporation v Wyeth LLC (No 3) FCA 1477 Summary Australia’s Federal Court has delivered judgment in...

20th Oct 2020

Australian Patent Office considers the plausibility of Swiss-style claims

Gliknik, Inc. v CSL Behring Lengnau AG APO 46 (“Gliknik”) concerned a patent application for engineered proteins intended for use as replacements for intravenous immunoglobulin. The application included claims...

Gliknik, Inc. v CSL Behring Lengnau AG APO 46 (“Gliknik”) concerned a patent application for engineered proteins intended for...

15th Oct 2020

Intervet parries a challenge to its combination injectable anthelmintic formulation patent application

Boehringer Ingelheim Animal Health USA Inc. v Intervet International B.V. FCA 1333 Key takeaways: For novelty purposes, expert evidence does not make up for a lack of sufficiently clear and...

Boehringer Ingelheim Animal Health USA Inc. v Intervet International B.V. FCA 1333 Key takeaways: For novelty purposes, expert evidence does...

21st Sep 2020

Pharmaceutical patent term extensions: broader is not always better

Ono Pharmaceutical Co., Ltd. et al APO 43 (16 September 2020) Background Australia’s Patents Act provides a patent term extension (PTE) to account for the delays that can occur when obtaining...

Ono Pharmaceutical Co., Ltd. et al APO 43 (16 September 2020) Background Australia’s Patents Act provides a patent term extension (PTE)...

16th Jul 2020

Clinical trial protocols anticipate method of treatment claims, and further clarity provided on construction of Swiss-style claims

Australia’s Full Federal Court recently delivered judgment in an appeal in a significant patent case: Mylan Health Pty Ltd v Sun Pharma ANZ Pty Ltd FCAFC 116. The case concerned...

Australia’s Full Federal Court recently delivered judgment in an appeal in a significant patent case: Mylan Health Pty Ltd v...